In English | En español
Questions About Cancer? 1-800-4-CANCER
 Translucent plastic bag containing bevacizumab and other chemo drugs dripping through I.V. port

Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer

February 7, 2013

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

Read Full Article